This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singhal, S. S. Articles by Awasthi, S. Search for Related Content PubMed PubMed Citation Articles by Singhal, S. S. Articles by Awasthi, S.

Regression of Melanoma in a Murine Model by RLIP76 Depletion

¹ Department of Chemistry and Biochemistry, University of Texas at Arlington, Arlington and ² Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch at Galveston, Galveston, Texas

Requests for reprints: Sanjay Awasthi, Department of Chemistry and Biochemistry, 502 Yates Street, Science Hall Room 223, University of Texas at Arlington, Arlington, TX 76019-0065. Phone: 817-272-5444; Fax: 817-272-3808; E-mail: sawasthi{at}uta.edu.

RLIP76/RALBP1 is a stress-responsive membrane protein implicated in the regulation of multiple cellular signaling pathways. It represents the predominant glutathione-conjugate transporter in cells, and our previous studies have shown that its inhibition by antibodies or depletion by short interfering RNA (siRNA) causes apoptosis in a number of cancer cell types. The present studies were done to explore the potential clinical applicability of our previous observations by comparing the relative expression of RLIP76 in cancer versus normal cell lines and to determine whether depletion of RLIP76 activity can exert cancer-specific apoptosis. RLIP76 expression was found to be significantly greater in malignant cells compared to nonmalignant cells. Inhibition of RLIP76, using antibodies towards a cell surface epitope, or depletion of RLIP76 using either siRNA or antisense phosphorothioate oligonucleotides preferentially caused apoptosis in malignant cells. More importantly, in vivo studies showed that administration of RLIP76 antibodies, siRNA, or antisense oligonucleotides to mice bearing syngeneic B16 mouse melanoma cells caused complete tumor regression within 10 days. These findings strongly suggest that RLIP76 depletion by genetic approaches or inhibition by antibodies may be a clinically viable antineoplastic therapy, particularly for melanoma. (Cancer Res 2006; 66(4): 2354-60)

This article has been cited by other articles:

				S. Awasthi, S. S. Singhal, Y. C. Awasthi, B. Martin, J.-H. Woo, C. C. Cunningham, and A. E. Frankel RLIP76 and Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4372 - 4377. [Abstract] [Full Text] [PDF]

				S. S. Singhal, S. Yadav, K. Drake, J. Singhal, and S. Awasthi Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1 J. Biol. Chem., July 11, 2008; 283(28): 19714 - 19729. [Abstract] [Full Text] [PDF]

				P. Margutti, P. Matarrese, F. Conti, T. Colasanti, F. Delunardo, A. Capozzi, T. Garofalo, E. Profumo, R. Rigano, A. Siracusano, et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis Blood, May 1, 2008; 111(9): 4559 - 4570. [Abstract] [Full Text] [PDF]

				S. S. Singhal, J. Singhal, S. Yadav, S. Dwivedi, P. J. Boor, Y. C. Awasthi, and S. Awasthi Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein 1) Cancer Res., May 1, 2007; 67(9): 4382 - 4389. [Abstract] [Full Text] [PDF]